Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial:

Dementia Big
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.

http://ift.tt/2rCCKzn